About 34% of cases exhibit mixed osteolytic and osteoblastic features, requiring differentiation from osteosarcoma (marked by a 5-fold elevation in alkaline phosphatase) and metastatic breast cancer (estrogen receptor/progesterone receptor positivity) (35, 51, 52). The gene discussed is ESR1; the disease is osteosarcoma.